Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Exercise as young adult tied to heart health decades later
30 Nov 2015 at 1:35pm
By Lisa Rapaport (Reuters Health) - Young adults who exercise may have a lower risk of cardiovascular disease and higher survival odds decades later than their peers who aren?t as active early in life, a U.S. study suggests. Fitness has long been linked to a reduced risk of heart disease in older adults. ?Each additional minute a person could exercise on a treadmill in early adulthood was associated with substantially lower likelihood of risk of dying or developing cardiovascular diseases over 25 years later,? lead study author Dr. Ravi Shah of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston said by email.
Doctors' use of computers during appointments leaves patients less satisfied
30 Nov 2015 at 1:33pm
By Kathryn Doyle (Reuters Health) - Doctors who entered data into computerized health records during patients' appointments did less positive communicating, and patients rated their care excellent less often, in a recent study. ?Many clinicians worry that electronic health records keep them from connecting with their patients,? said Dr. Neda Ratanawongsa of the University of California, San Francisco, who co-authored the research letter. ?So it's not surprising that we found differences in the way clinicians and patients talk to each other,? she said.
Alabama ends court fight over Planned Parenthood funding
30 Nov 2015 at 1:25pm
Alabama called off a legal battle with Planned Parenthood on Monday after a federal judge last month blocked the state from defunding the reproductive health organization's clinics amid national controversy about its handling of aborted fetal tissue. In a joint court filing, both parties said that Alabama had resumed funding of Planned Parenthood clinics in Mobile and Birmingham, and the clinics were following state regulations. The agreement followed an order by U.S. District Judge Myron Thompson to stop Alabama from terminating its agreement with a Planned Parenthood regional affiliate providing services under Medicaid, the federal and state healthcare program for the poor.
Pope admits Church finds condom use against AIDS 'complicated' issue
30 Nov 2015 at 1:22pm
Pope Francis admitted Monday the question as to whether the Church should allow the use of condoms in the fight against AIDS was a "complicated" one, but he said the world had bigger problems. Grilled on the eve of World AIDS Day about the Roman Catholic Church's controversial opposition to condoms, the Argentine pontiff admitted the issue was "morally complicated for the Church", but refused to be drawn into a debate. The Church is against all forms of contraception and instead says abstinence is the best way to avoid spreading AIDS.
Suspect in Colorado clinic shooting told he faces murder charge
30 Nov 2015 at 1:14pm
By Keith Coffman COLORADO SPRINGS, Colo. (Reuters) - The man accused of killing three people and wounding nine in a shooting rampage at a Planned Parenthood clinic in Colorado Springs was told he faces charges including first-degree murder during his first court appearance on Monday. Robert Lewis Dear, 57, appearing by video link from jail, spoke only to tell the judge he had no questions. There was no discussion of the suspect's motives during the brief hearing, and formal charges will be filed at a court appearance scheduled for Dec. 9.
Top carbon culprits US, China, India debate nuances of roles
30 Nov 2015 at 1:13pm
LE BOURGET, France (AP) ? Call them the culprits of carbon.
Certain birth defects linked to abuse of infants and toddlers
30 Nov 2015 at 1:11pm
By Lisa Rapaport (Reuters Health) - Babies with certain birth defects are much more likely to be abused as infants and toddlers than other young children, a U.S. study suggests. Babies with malformations of the mouth and jaw known as cleft lip and palate were 40 percent more likely to be abused by their second birthday than those born without birth defects, the analysis of about 3 million children in Texas found. For infants born with spina bifida, a spinal cord disorder linked to lower limb paralysis and cognitive delays, the odds of maltreatment were 58 percent higher, researchers reported in the journal Pediatrics.
The Healthiest Nut You Should Be Eating This Holiday Season
30 Nov 2015 at 12:55pm
By Emily Giunta, dailyRx NewsCould a handful of walnuts a day really keep the doctor away? For patients at risk for Type 2 diabetes, perhaps.A new study found that eating a handful of walnuts every day may be linked to better diet quality overall and improvements in certain Type 2 diabetes risk factors among high-risk patients.Patients in this...
First police trial in Freddie Gray killing begins with jury selection
30 Nov 2015 at 12:52pm
By Ian Simpson BALTIMORE (Reuters) - Jury selection began on Monday in the trial of the first of six police officers charged in the April death of a black man from an injury in police custody that set off rioting in Baltimore and inflamed the U.S. debate on race and justice. The death of Freddie Gray, 25, followed police killings of black men in other cities, including New York and Ferguson, Missouri, that gave rise to the Black Lives Matter movement, which has staged more than year of mostly peaceful protests across the United States. Some 20 protesters assembled outside the downtown courthouse where jury selection was underway.
Nina and the Dancing Bees
30 Nov 2015 at 12:51pm
In the midst of the Greek crisis, life can still be sweet.In Greece motorbikes are everywhere. While bareheaded locals and helmeted tourists careen along coastal roads, there is one four wheeler here on Aegina Island that is unique and familiar; it has a beehive strapped on the back. It belongs to Nina Stergiopoulou, keeper of bees.The Greek...
Fun Can Increase Weight Loss!
30 Nov 2015 at 12:29pm
All Work & No Play Leads To Weight Gain! I'm en route back from a business trip in New York, where I made sure to mix in some FUN time with my baby boy, friends, and family. This is something I started to do years ago, making sure I had FUN and life wasn't just work, work, work.Why?Because after working with thousands of women for over a...
Northern Irish abortion laws breach human rights: court
30 Nov 2015 at 12:06pm
By Ian Graham BELFAST (Reuters) - Northern Ireland's restrictive abortion laws are in breach of human rights by failing to provide exceptions in the case of fatal foetal abnormality and sexual crime, Belfast's High Court found in a landmark ruling on Monday. Unlike other parts of the United Kingdom, abortion is banned in Northern Ireland unless the life or mental health of the mother is in danger. After four months of deliberation, Judge Mark Horner upheld a challenge by the Northern Ireland Human Rights Commission that the laws breached the European Convention on Human Rights and asked the parties involved to consider whether the ruling could be applied under current legislation.
NYC's novel salt warning rule set to take effect at chains
30 Nov 2015 at 11:53am
NEW YORK (AP) ? New York City begins a new era in nutritional warnings this week, when chain restaurants will have to start putting a special symbol on highly salty dishes.
'Live positively': Togo's 'Tino' sets example for HIV/AIDS
30 Nov 2015 at 11:52am
Augustin Dokla is arguably Togo's most famous person with HIV, having lived with the virus -- against the odds ?- since 1999. Among friends at Espoir-Vie, the West African nation's largest non-governmental association for people living with HIV, Dokla exudes optimism. Dokla tested positive for HIV in 1999 after a bout of serious pneumonia, which saw him spend three months in hospital.
AP News Guide: Summit opens debate on ethics of gene editing
30 Nov 2015 at 11:26am
Designer babies or an end to intractable illnesses: A revolutionary technology is letting scientists learn to rewrite the genetic code, aiming to alter DNA in ways that, among other things, could erase disease-causing genes.